Iannitto E, Accurso V, Federico M, Vallisa D, Pieresca C, Gravina S F, Di Costanzo F, Di Trapani R, Silingardi V, Mariani G
Ematologia e Centro Trapianto di Midollo, Università di Palermo, Italy.
Haematologica. 1997 Nov-Dec;82(6):676-82.
Infradiaphragmatic Hodgkin's disease is rare, making up 5-12% of cases in clinical stages I and II; consequently, several questions concerning prognosis and treatment strategy remain to be answered. The aim of this study was to analyze the clinical and prognostic characteristics and outcome of this condition.
A series of 282 patients with CS I-II Hodgkin's disease (HD) was investigated. In 31 patients the disease was confined below the diaphragm (BDHD), and in the remaining above the diaphragm (ADHD). The presenting features and outcomes were compared in the two groups.
The BDHD group was older (p < 0.0002), had a higher frequency of males (p < 0.08) and a different histological subtype group distribution (p < 0.0001). Stage II BDHD patients had a worse overall survival rate (OS) than stage II ADHD patients (68.8% vs 86.6% at 8 years, p < 0.01) if age is not considered; patients with more than 40 years of age, in fact, had the same survival rates as those with ADHD. BDHD patients with intra-abdominal disease alone had worse prognostic factors and OS (p = 0.12) than patients with inguinal-femoral nodes.
Although BDHD patients present distinct features, they have the same OS and relapse-free survival rate as age-adjusted ADHD patients. According to our experience patients with stage I peripheral BDHD respond well to radiotherapy-based regimens. Those with stage II and or intra-abdominal disease are more challenging; chemotherapy or a combined therapy seem to be more suitable approaches for these patients.
膈下霍奇金病较为罕见,在临床I期和II期病例中占5%-12%;因此,关于预后和治疗策略的几个问题仍有待解答。本研究的目的是分析这种疾病的临床和预后特征及结果。
对一系列282例CS I-II期霍奇金病(HD)患者进行了研究。其中31例患者疾病局限于膈肌以下(BDHD),其余患者疾病位于膈肌以上(ADHD)。比较了两组的临床表现和结果。
BDHD组患者年龄较大(p<0.0002),男性比例较高(p<0.08),组织学亚型分布不同(p<0.0001)。如果不考虑年龄,II期BDHD患者的总生存率(OS)低于II期ADHD患者(8年时分别为68.8%和86.6%,p<0.01);事实上,年龄超过40岁的患者生存率与ADHD患者相同。单纯腹内疾病的BDHD患者预后因素和OS比腹股沟-股淋巴结患者差(p=0.12)。
尽管BDHD患者有不同特征,但与年龄调整后的ADHD患者相比,他们的OS和无复发生存率相同。根据我们的经验,I期外周BDHD患者对基于放疗的方案反应良好。II期和/或腹内疾病患者更具挑战性;化疗或联合治疗似乎是这些患者更合适的治疗方法。